+
HeatStroke Rapid Test

RESUME

TAKESHI SUGAYA, Ph.D.

As of October 3, 2025

E-mail: takeshi-sugaya@marianna-u.ac.jp

Educational Details

  • 1999 - Ph.D., received from Institute of Applied Biochemistry, the University of Tsukuba
  • 1986-1989 - Master Course of Industrial Chemistry, Graduate School of Engineering, Kyoto University
  • 1982-1986 - Faculty of Industrial Chemistry, Department of Engineering, Kyoto University

Working Experiences

  • 2020-Present - Chief Technology Officer and Scientific Founder, Timewell Medical Co., Ltd.
  • 2006-2020 - Senior Director, L-FABP Business Department, CMIC Holdings Co., Ltd.
  • 1989-2006 - Research Leader of the Nephrology Group, Tanabe Pharmaceutical Co., Ltd.

Research Experiences

  • 2005-Present - Guest Professor of Department of Nephrology and Hypertension, School of Medicine of St. Marianna University, Kanagawa
  • 2012-2013 - Visiting Scientist of The Methodist Hospital Research Institute, Houston, Texas
  • 2005-2008 - Researcher and organizing committee of the grant research on Human Genome and Regeneration commissioned by Ministry of Health, Labour and Welfare
  • 2004-2008 - Visiting researcher of Organ Regeneration Unit, Center for Developmental Biology, RIKEN institute
  • 2000-2002 - Researcher of the grant research on Child Health and Development commissioned by Ministry of Health, Labour and Welfare
  • 1997-2006 - Invited researcher of TARA (Tsukuba Advanced Research Alliance) in the University of Tsukuba

Teaching Experiences

  • 2023 - Guest Professor of Integrated Science Faculty, Hiroshima University
  • 2004-Present - Visiting Lecturer of Department of Nephrology, School of Medicine, Juntendo University
  • 2004-2016 - Visiting Lecturer of Cornea Center, Tokyo Dental College

Affiliation

  • 2013-2019 - Working Group Member of Japanese Society of Nephrology/ Global Outreach for Sister Renal Center
  • 2007-2018 - Vice Chairman, Working Group for Promotion of Panelized Urine Biomarker, Japanese Society of Nephrology
  • 2007-2012 - Active Member of Acute Kidney Injury Network (AKIN)
  • 2005-2020 - Active Member of European Diabetic Nephropathy Study Group (EDNSG)

Academic Achievement

  • 2022 - Excellent Presentation Award, Japanese Society of Nephrology
  • 2015 - Excellent Poster Award, The Japanese Society of Toxicology
  • 1997 - CVEM Young Investor Award, Japanese Society of Cardiovascular Endocrinology and Metabolism

Specialized Area

Takeshi Sugaya has a practical experience in developing anti-hypertension drugs, medical devices and renal biomarkers listed in global guidelines through regulatory approval and scientific activities at pharmaceutical companies and start-up of venture companies.

Key words: Nephrology, Biomarker, Renin-Angiotensin System, Fatty Acid Binding Protein, Heatstroke, Basic and clinical research on cardio-renal diseases, Establishment of therapeutic and prognosis method of kidney diseases.

Bibliography

Number of English publications: 209 peer-reviewed articles, 9 reviews and 2 book chapters

Selected Peer-Reviewed Articles

  1. Sugaya T, Nishimatsu S, Tanimoto K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270: 18719-18722, 1995
  2. Hisada Y, Sugaya T, Yamanouchi M, et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103: 627-635, 1999
  3. Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100: 2093-2099, 1999
  4. Sasaki K, Murohara T, Ikeda H, et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 109: 603-611, 2002
  5. Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid binding protein reflects stress overload on the proximal tubules. Am J Pathol 165: 1243-1255, 2004
  6. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of Pitavastatin on urinary liver-type fatty acid-protein levels in patients with early diabetic nephropathy. Diabetes Care 28(11):2728-2732, 2005
  7. Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 47(3):439-444, 2006
  8. Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 18(11):2894-2902, 2007
  9. Noiri E, Doi K, Negishi K, et al. Urinary fatty acid binding protein 1: An early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 296:669-679, 2009
  10. Nielsen SE, Sugaya T, Hovind P, et al. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33(6):1320-1324, 2010
  11. Doi K, Noiri E, Maeda-Mamiya R, et al. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med. 38(10):2037-2042, 2010
  12. Kamijo-Ikemori A, Sugaya T, Yasuda T, et al. Clinical Significance of Urinary Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients. Diabetes Care 34(3):691-696, 2011
  13. Ichikawa D, Kamijo-Ikemori A, Sugaya T, et al. Renal Liver-Type Fatty Acid Binding Protein Attenuates Angiotensin II-Induced Renal Injury. Hypertension. 60(4):973-980, 2012
  14. Fujita D, Takahashi M, Doi K, et al. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease. Heart Vessels. 30(3):296-303, 2015
  15. Obata Y, Kamijo-Ikemori A, Ichikawa D, et al. Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair. J Anesth. 30(1):89-99, 2016
  16. Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 94(3):524-535, 2018
  17. Eguchi A, Hasegawa H, Iwasa M, et al. Serum Liver-Type Fatty Acid-Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma. Hepatol Commun., 3(6):825-837, 2019
  18. Yepes-Calderón M, Sotomayor CG, Pena M, et al. Urinary liver-type fatty acid-binding protein is independently associated with graft failure in outpatient kidney transplant recipients. Am J Transplant., 21(4):1535-154. 2021
  19. Kosaki K, Kumamoto S, Tokinoya K, et al. Xanthine Oxidoreductase Activity in Marathon Runners: Potential Implications for Marathon-Induced Acute Kidney Injury. J Appl Physiol. 1;133(1):1-10. 2022
  20. Peabody J, Paculdo D, Valdenor C, et al. Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures. Cardiorenal Med. 14:1-9. 2022
  21. Katagiri D, Asai Y, Ohmagari N, et al. Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases. Crit Care Explor. 9;5(3):e0873. 2023
  22. Goto H, Ishikiriyama T, Oe K, et al. Liver fatty acid-binding protein point-of-care testing detects heat-induced organ damage: a pilot study in Japanese male self-defense force personnel. Sci Rep. 15(1):7197. 2025

Reviews

  1. Lafayette RA, Hisada Y, Sugaya T: "How does knocking out angiotensin II activity reduce renal injury in mice?" Am J Kidney Dis. 35: 166-172, 2000
  2. Mayer GL, Sugaya T. Urinary L-FABP: A Novel Biomarker for Renal Disease and Its Role in the Diagnosis and Prognosis of Chronic and Acute Kidney Disease. The Fats of Life. Volume XX(1):4-12, 2006
  3. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 374(1-2):1-7, 2006
  4. Noiri E, Doi K, Negishi K, et al. Urinary fatty acid binding protein 1: An early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 296:669-679, 2009
  5. Doi K, Noiri E, Sugaya T. Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care. Curr Opin Crit Care. 16(6):545-459, 2010
  6. Kamijo-Ikemori A, Sugaya T, Ichikawa D, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 424:104-108, 2013
  7. Kamijo-Ikemori A, Sugaya T, Kimura K. Novel urinary biomarkers in early diabetic kidney disease. Curr Diab Rep. 14(8):513, 2014
  8. Eiichi Sato, Atsuko Kamijo-Ikemori, Tsuyoshi Oikawa, et al. Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Renal Replacement Therapy, doi:10.1186. 2017
  9. Noiri E, Katagiri D, Asai Y, Sugaya T, Tokunaga K. Urine oxygenation predicts COVID-19 risk. Clin Exp Nephrol. 28(7):608–616, 2024

Book Chapters

  1. Noiri E, Hamasaki Y, Negishi K, et al. The Potential of Urinary Tests in the Management of Kala-Azar, 69-90, "Kala Azar in South Asia" Chapter 8, Springer 2011
  2. Oikawa T, Sugaya T. Urinary L-FABP: a novel biomarker for the diagnosis and prognosis of chronic and acute kidney disease. "Oxidative Stress in Applied Basic Research and Clinical Practice - Pediatric Disorders" Chapter 7, Springer 2014